(Q24240554)

10

0 references

Meg Jardine

Meg J Jardine

4

0 references

Alan Cass

Alan Cass

2

0 references

Giovanni Strippoli

9

Giovanni FM Strippoli

0 references

Sankar Navaneethan

7

Sankar D Navaneethan

0 references

Sagar U Nigwekar

1

Sagar U Nigwekar

0 references

Amy Kang

5

Amy Kang

0 references

Satyarth Kulshrestha

6

Satyarth Kulshrestha

0 references

author name string

Martin P Gallagher

Cochrane Database of Systematic Reviews

3

0 references

publication date

15 April 2009

0 references

published in

0 references

cites work

Premature cardiovascular disease in chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Impact of malnutrition-inflammation on the association between homocysteine and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Folic acid supplementation to prevent adverse events in individuals with chronic kidney disease and end stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Effects of folic acid before and after vitamin B12 on plasma homocysteine concentrations in hemodialysis patients with known MTHFR genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Randomized, placebo-controlled trial of intramuscular vitamin B12 for the treatment of hyperhomocysteinaemia in dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Classical homocystinuria: vascular risk and its prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3

inferred from DOI database lookup

7 January 2021

based on heuristic

Cardiovascular disease and the kidney. Tracking a killer in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB3